Netscribes (India) Pvt. Ltd., a knowledge consulting solutions company, announces the launch of its Anti-Diabetic Pharmaceuticals Market in India 2011 report. India being the second largest diabetic pool in the world, the market is expected to show steady growth in the coming years. The report begins with the introduction section which offers a brief classification of the different types of diabetes. It then gives a classification of the diabetes market, and then provides a brief description of different classes of diabetes pharmaceuticals. The market overview section provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. It also provides a global diabetes map. An analysis of the drivers explains the factors for growth of the industry including increasing diabetes cases, introduction of newer and better drugs, increasing aging population and increase in health insurance policies. The key challenges include price regulation in the insulin market, competition from use of complementary and alternative medicines and maintainence of a healthy lifestyle to avoid diabetes. The government initiatives section gives a brief description of the different diabetes programmes undertaken by the Government. A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals for diabetes drugs. The competition section provides an overview of the competitive landscape in the industry. It includes a brief profile of the major players in the market along with their financials. It also includes the latest developments in the industry.

1. Insert Cover Image using Slide Master View
Do not distort
Anti-Diabetic Pharmaceuticals Market - India
August 2011

2. Executive Summary
Anti-diabetic pharmaceuticals market in India is valued at INR 22.54 bn in 2010
Market Market is expected to grow at a CAGR of 11% from 2010 to 2015
Anti-diabetes therapeutic segment is the second fastest growing segment, after oncology
Drivers: Challenges:
Increase in the number of diabetic Price regulation in insulin market
patients Use of complementary and alternative
medicines
E
Drivers and Introduction of newer and better drugs
L
Challenges Maintainence of healthy lifestyle to avoid
Increasing aging population diabetes
covering diabetes
MP
Comprehensive health insurances policies
SA
Phases of clinical trial
Drug regulation
Approval and licensing of drugs
and patents Patents
Highly fragmented market with large number of players
Competition Major foreign players in the market include Novo Nordisk, Eli Lilly and Glaxosmithkline
Major domestic companies include Panacea Biotech, Strides Arcolab, Torrent Pharmaceuticals,
Ranbaxy, Dr. Reddy’s, Cipla, Sun Pharmaceuticals, among others
Strategic Foray into the insulin delivery market
recommendations Collaboration with private hospitals
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 2

3. •Introduction
•Market Overview
•Drivers & Challenges
•Government Initiatives
•Drug Regulation and Patents
•Competition
•Strategic recommendation
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 3

4. India’s diabetes market is poised to grow over the coming
years
Indian Market – Overview Market Size and Growth
• India is considered to be one of the most lucrative
diabetes markets in the world INR bn
• Anti-diabetics represent the second fastest growing y% F
therapeutic segment among all the segments ,after 40 E
D
oncology 30 B C
• Market is expected to grow from INR A bn to INR B bn A
in 20--, at a CAGR of y% 20
• Biguanides, Gliclazide, Gliclazide with metformine, 10
Rosiglitazone and Pioglitazone are the top selling drugs
in Indian market
• Human Mixard 30/70 is the largest selling insulin in
Indian market
It showed largest growth among the top 10 brands in Indian
PLE 0
2010 2011e 2012e 2013e 2014e 2015e
M
Pharmaceutical market
A
Growth in therapeutic segments(2010) Market Segmentation
oncology
diabetes
0 5 10 15 20 25
b
30
S35
a
%
X1
Drugs
Insulin
Y2
CVS c
X2
CNS d
Y1
respiratory e
pain f
gastro g
anti-infectives h
Source:
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 4

5. Drivers & Challenges
Challenges
Drivers Price regulation in insulin market
Increase in the number of diabetic Competition from complementary and
patients alternative medicines
Introduction of newer and better Maintainence of healthy lifestyle to
drugs avoid diabetes
Increasing aging population
Increase in health insurances
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 5

6. Various initiatives taken by the government is providing a
boost to this market
• ICDC ,registered under Planning Commission, Government of India, is the only organisation in
India providing doorstep diabetes care
• ICDC implements National Doorstep Diabetes Identification and follow-up programme
through Grass Root Level NGOs all over India
Indian Council for • ICDC affiliates NGOs as Partner Organisation and reach people who are suffering with Diabetes and help
Diabetic Care them to control diabetes and live without any complications
• ICDC provides free glucometer and 100 Strips to the NGOs to start identifying the diabetes patients even
in villages
• ICDC is making efforts to provide medical insurance to the diabetes patients through Government of India
LE
as in the case of family planning insurance scheme
MP
• National Programme for prevention and Control of Diabetes, Cardiovascular diseases and
Stroke (NPCDCS) was started in 2008,with the objective of prevention, diagnosis and early
NPCDCS
management of diabetes
SA
• It is already being implemented in 100 most backward and remote districts spread across 21 states
• Indian Government plans to extend this programme to all the 650 districts of the country under the 12th
five year plan
• National Rural Health Mission is providing services for diabetes care in rural India
NRHM • Seeks to provide effective healthcare to rural population throughout the country with special
focus on 18 states
Source:
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 6

7. Major domestic players in the market (1/9)
Company Snapshot: Company 1
Corporate Information Financial Performance
Revenue Revenue Profit
Headquarters City 1, country 1
INR tn INR bn
Profit / Loss
Founded 19-- 3 2.0
r2 r3 r4
r1 1.5
2
Products Product 1, product 2, product 3 1.0
1
LE
0.5
Key People Person X, CEO
0 0.0
Business Highlights
MP 2007 2008 2009 2010
• Company employs around n people
SA
• Product portfolio includes prescription products in various therapeutic areas, segment A, segment B, segment C
• Anti-diabetes products include Product 1, Product 2, Product 3
• Company has collaboration agreements with Institute Y
Source: Note: Figures are for year ending 31st December
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 7

8. Thank you for the attention
The Anti-Diabetic Pharmaceuticals Market – India report is part of Netscribes’ Healthcare
Industry Series.
For more detailed information or customized research requirements please contact:
Tamojit Roy Gagan Uppal
Phone: +91 33 4064 6215 Phone: +91 22 4098 7530
E-Mail: tamojit.roy@netscribes.com E-Mail: gagan.uppal@netscribes.com
Research on India is a product of Netscribes (India) Pvt. Ltd. Research on India is dedicated to disseminating information and providing quick
insights on “hot” industries in India and other emerging markets. Track our new releases and major updates in these industries on
About Netscribes
Netscribes is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients’ profitability and growth
objectives.
Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Research on India,
Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the
sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.
ANTI-DIABETES PHARMACEUTICALS MARKET 2011.PPT 8